<div id="readability-page-1"><p>Haemonetics (NYSE:HAE - Get Free Report) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 4.700-5.00 for the period, compared to the consensus estimate of 4.866. The company issued revenue guidance of -.</p><h2>Haemonetics Stock Performance</h2><p>Shares of NYSE HAE opened at $75.81 on Thursday. The company has a 50 day simple moving average of $73.24 and a two-hundred day simple moving average of $67.65. The stock has a market cap of $3.64 billion, a price-to-earnings ratio of 22.90, a PEG ratio of 1.23 and a beta of 0.40. The company has a current ratio of 1.62, a quick ratio of 0.99 and a debt-to-equity ratio of 1.12. Haemonetics has a 12 month low of $55.30 and a 12 month high of $94.99. </p><p>Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.08. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%.  As a group, analysts predict that  Haemonetics will post 4.55 earnings per share for the current year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>HAE has been the subject of several recent research reports. Raymond James Financial  reiterated a &#34;strong-buy&#34; rating and set a $105.00 price target (down from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Citigroup raised shares of Haemonetics from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and set a $90.00 target price for the company in a report on Wednesday, July 9th. Needham &amp; Company LLC dropped their price target on shares of Haemonetics from $104.00 to $84.00 and set a &#34;buy&#34; rating on the stock in a research report on Thursday, May 8th. Robert W. Baird initiated coverage on Haemonetics in a report on Thursday, June 26th. They set an &#34;outperform&#34; rating and a $87.00 target price for the company. Finally, Baird R W raised Haemonetics to a &#34;strong-buy&#34; rating in a research note on Wednesday, June 25th. One equities research analyst  has rated the stock with a sell rating, one  has issued  a hold rating, eight have issued  a buy rating and two have issued  a strong buy rating to the company. According to data from MarketBeat.com, Haemonetics  has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $97.30.</p><p><b>View Our Latest Research Report on Haemonetics</b></p><h2>Institutional Investors Weigh In On Haemonetics</h2><p>Several hedge funds and other institutional investors have recently bought and sold shares of the company. Strs Ohio purchased a new stake in shares of  Haemonetics in the 1st quarter valued at approximately $140,000.  United Services Automobile Association purchased a new stake in  Haemonetics during the 1st quarter worth about $212,000.  Caxton Associates LLP acquired a new stake in  Haemonetics in the 1st quarter valued at about $216,000.  Empowered Funds LLC raised its position in  Haemonetics by 9.1% in the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier's stock valued at $283,000 after purchasing an additional 372 shares in the last quarter.  Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of  Haemonetics by 3.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier's stock valued at $1,877,000 after buying an additional 971 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds. </p><h2>About Haemonetics</h2> (Get Free Report)<p>Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.</p><h2>See Also</h2><ul><li>Five stocks we like better than Haemonetics</li><li>What Are Dividend Champions? How to Invest in the Champions</li><li>Buybacks Over Dividends? These 2 Stock Picks Make a Strong Case</li><li>How to Invest in Blue Chip Stocks</li><li>Navitas Stock's Dip: A Calculated Risk or a Clear Buy Signal?</li><li>What is Short Interest? How to Use It</li><li>Buy the Dip? These Earnings Misses Offer Long-Term Upside</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUhBRQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Haemonetics Right Now?</h2><p>Before you consider Haemonetics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.</p><p>While Haemonetics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Haemonetics (NYSE:HAE) has updated its FY 2026 earnings guidance, projecting EPS between 4.700 and 5.00, slightly above the consensus estimate of 4.866. The company's stock opened at $75.81, with a market cap of $3.64 billion. Analysts have mixed ratings, with a consensus price target of $97.30. Institutional investors hold 99.67% of the stock. Haemonetics specializes in medical products and solutions, including automated plasma collection systems and donor management software.</p>

Haemonetics (NYSE:HAE) Releases FY 2026 Earnings Guidance